Crossmark

Chimeric antigen receptor T-cell therapies for lymphoma

Crossref DOI link: https://doi.org/10.1038/nrclinonc.2017.128

Published Online: 2017-08-31

Published Print: 2018-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Brudno, Jennifer N.

Kochenderfer, James N.
License Information

Text and Data Mining valid from 2017-08-31
More Information

Article History

First Online: 31 August 2017

Competing interests

: J.N.K. receives research funding from cooperative research and development agreements between the National Cancer Institute (NCI) and Kite Pharma, and between the NCI and Bluebird Bio. J.N.K. also has multiple patent applications related to chimeric antigen receptors (CARs). J.N.B. declares no competing interests.